In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Albireo AB

Division of Albireo Pharma Inc.
http://www.albireopharma.com

Latest From Albireo AB

Pipeline Watch: Top-Line Lanadelumab, Inotersen, Durvalumab Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

PIPELINE WATCH: A Strong Analgesic Meets Primary Endpoint, But An RNAi Therapeutic Disappoints

Pipeline Watch has been updated to bring greater depth and detail to a product’s progress through the R&D pipeline, and is now a snapshot of late-stage, Phase II and III clinical trial events for drugs being evaluated by the pharma and biotech industries that is now available to view.

Pipeline Watch Approvals

AstraZeneca’s Seasoned Dealmaker Grady On Strategy To Grow Pipeline

AstraZeneca’s Shaun Grady is an affable dealmaker whose talents – honed over three decades inside the group – are being put to the test as global business development head to help ensure Britain’s second-biggest drugmaker can successfully transform itself, its therapy focus and pipeline. He tells In Vivo about his role leading AZ’s transaction execution, due diligence and alliance and integration management, while overseeing its collaborative “externalization” program, licensing and partnering, M&A and divestments.

Business Strategies Deals

INTERVIEW: Finding Stars And Staying Independent, Biotech Veteran David Chiswell's Five Year Plan

David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.

United Kingdom Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Albireo Pharma Inc.
  • Senior Management
  • Ron Cooper, Pres. & CEO
    Per-Goran Gillberg, PhD, VP, Dev.
    Hans Graffner, MD, PhD, CMO
  • Contact Info
  • Albireo AB
    Phone: (46) 31 741 14 80
    Arvid Wallgrens Backe 20
    Gothenburg, 413 46
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register